Cargando…

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

BACKGROUND: The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the sign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakano, Kazuhiko, Ohta, Shigeyuki, Komatsu, Kenji, Kubo, Taro, Nukui, Akinori, Suzuki, Kazumi, Kurokawa, Shinsuke, Kobayashi, Minoru, Morita, Tatsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305626/ https://www.ncbi.nlm.nih.gov/pubmed/22353627 http://dx.doi.org/10.1186/1471-2490-12-3

Ejemplares similares

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
por: Nakano, Kazuhiko, et al.
Publicado: (2014)

Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
por: Morita, Tatsuo
Publicado: (2010)

Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines.
por: von Schoultz, E., et al.
Publicado: (1988)

Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.
por: Bergenheim, A. T., et al.
Publicado: (1993)

Comparison of Ketoconazole and Estramustine for Treating Patients with Castration-Resistant Prostate Cancer
por: Yun, Bu Hyeon, et al.
Publicado: (2011)

Effects of radiotherapy and estramustine on the microvasculature in malignant glioma
por: Johansson, M, et al.
Publicado: (1999)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer
por: Albrecht, W, et al.
Publicado: (2004)

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis
por: Qin, Zhiqiang, et al.
Publicado: (2016)

Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
por: Speicher, L. A., et al.
Publicado: (1991)

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
por: Carles, J, et al.
Publicado: (2007)

Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia
por: Morita, Tatsuo, et al.
Publicado: (2013)

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
por: Hernes, E. H., et al.
Publicado: (1997)

Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion.
por: Behnam-Motlagh, P., et al.
Publicado: (1997)

Estramustine Phosphate Inhibits TGF-β-Induced Mouse Macrophage Migration and Urokinase-Type Plasminogen Activator Production
por: Mojsilovic, Sonja S., et al.
Publicado: (2018)

DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain--suggesting an apoptotic cell death.
por: Vallbo, C., et al.
Publicado: (1995)

Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells
Publicado: (1988)

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
por: DiPaola, Robert S, et al.
Publicado: (2010)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

Approach via a small retroperitoneal anterior subcostal incision in the supine position for gasless laparoendoscopic single-port radical nephrectomy: initial experience of 42 patients
por: Morita, Tatsuo, et al.
Publicado: (2014)

Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis
por: Koie, Takuya, et al.
Publicado: (2014)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: a case report
por: Nakano, Kazuhiko, et al.
Publicado: (2012)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

A new simple technique of epididymal sperm collection for obstructive azoospermia
por: Morita, Tatsuo, et al.
Publicado: (2016)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
por: Kawahara, Takashi, et al.
Publicado: (2012)

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
por: Yamashita, Shimpei, et al.
Publicado: (2016)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qrihae4m5c5n0m4cr35rbtb58s